Brenda Furlow Net Worth

The estimated Net Worth of Brenda S. Furlow is at least $4.29 millió dollars as of 7 December 2022. Ms. Furlow owns over 8,250 units of Bio-Techne Corp stock worth over $2,465,002 and over the last 10 years she sold TECH stock worth over $0. In addition, she makes $1,823,660 as Senior Vice President, General Counsel és Corporate Secretary at Bio-Techne Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Furlow TECH stock SEC Form 4 insiders trading

Brenda has made over 16 trades of the Bio-Techne Corp stock since 2018, according to the Form 4 filled with the SEC. Most recently she exercised 8,250 units of TECH stock worth $257,895 on 7 December 2022.

The largest trade she's ever made was exercising 11,795 units of Bio-Techne Corp stock on 30 November 2020 worth over $1,257,229. On average, Brenda trades about 3,136 units every 59 days since 2014. As of 7 December 2022 she still owns at least 33,542 units of Bio-Techne Corp stock.

You can see the complete history of Ms. Furlow stock trades at the bottom of the page.

Brenda Furlow biography

Brenda S. Furlow J.D. is a Senior Vice President, General Counsel, Corporate Secretary of the Company. Prior to joining Bio-Techne, Ms. Furlow served as general counsel to emerging growth technology companies. Ms. Furlow was General Counsel for TomoTherapy, a global, publicly traded company that manufactured and sold radiation therapy equipment, from 2007 to 2011. From 1998 to 2007, Ms. Furlow served as General Counsel for Promega Corporation, a global life sciences company.

What is the salary of Brenda Furlow?

As the Senior Vice President, General Counsel és Corporate Secretary of Bio-Techne Corp, the total compensation of Brenda Furlow at Bio-Techne Corp is $1,823,660. There are 5 executives at Bio-Techne Corp getting paid more, with Charles Kummeth having the highest compensation of $11,483,800.

How old is Brenda Furlow?

Brenda Furlow is 62, she's been the Senior Vice President, General Counsel és Corporate Secretary of Bio-Techne Corp since 2014. There are 5 older and 14 younger executives at Bio-Techne Corp. The oldest executive at Bio-Techne Corp is Roeland Nusse, 70, who is the Independent Director.

What's Brenda Furlow's mailing address?

Brenda's mailing address filed with the SEC is 614 MCKINLEY PL N E, , MINNEAPOLIS, MN, 55413.

Insiders trading at Bio-Techne Corp

Over the last 22 years, insiders at Bio-Techne Corp have traded over $37,160,097 worth of Bio-Techne Corp stock and bought 4,361 units worth $454,370 . The most active insiders traders include Charles R. Kummeth, Rupert Vessey és John L Higgins. On average, Bio-Techne Corp executives and independent directors trade stock every 23 days with the average trade being worth of $964,850. The most recent stock trade was executed by Kim Kelderman on 29 August 2024, trading 1,492 units of TECH stock currently worth $99,919.

What does Bio-Techne Corp do?

bio-techne (formerly techne corp.), nasdaq: tech, is a global life sciences company providing innovative bioactive tools and resources for the research and clinical diagnostic communities. bio-techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. they aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. with over 275,000 products in its portfolio, bio-techne generated approximately $358 million in net sales in fy 2014 and has over 1,000 employees worldwide.

Complete history of Ms. Furlow stock trades at Bio-Techne Corp

Bio-Techne Corp executives and stock owners

Bio-Techne Corp executives and other stock owners filed with the SEC include:

• Charles Kummeth,
  President, Chief Executive Officer, Director
• Charles R. Kummeth,
  CEO, Pres & Director
• James Hippel,
  Chief Financial Officer, Executive Vice President - Finance
• David Eansor,
  President - Protein Sciences
• Kim Kelderman,
  President - Diagnostics and Genomics
• Brenda Furlow,
  Senior Vice President, General Counsel, Corporate Secretary
• James T. Hippel,
  Exec. VP of Fin. & CFO
• Norman David Eansor,
  Pres of Protein Sciences Segment
• Kim Kelderman,
  Pres of Diagnostics & Genomics
• Brenda S. Furlow J.D.,
  Exec. VP, Gen. Counsel, Sec. & Chief Compliance Officer
• Robert Baumgartner,
  Independent Chairman of the Board
• Rupert Vessey,
  Independent Director
• John Higgins,
  Independent Director
• Randolph Steer,
  Independent Director
• Roeland Nusse,
  Independent Director
• Alpna Seth,
  Independent Director
• Joseph Keegan,
  Independent Director
• David Clair,
  IR Contact Officer
• Julie Bushman,
  Independent Director
• Kevin Smyth,
  Sr. VP & Chief Digital Officer
• Luca Cicchetti,
  Managing Director
• Brenda Everson,
  Sr. VP of HR
• Kevin S. Gould,
  Sr. VP of Diagnostics Reagents Division
• Struan Robertson,
  VP of HR
• Robert M. Gavin,
  VP of Corp. Devel.
• Gerry Andros,
  VP of Sales and Marketing
• Karen A Holbrook,
  Director
• Roger C Lucas,
  
• Charles A Dinarello,
  
• J. Fernando Bazan,
  Chief Technical Officer
• Robert M. Gavin,
  Sen. VP Protein Platforms
• Kevin S Gould,
  SVP Clinical Controls
• Kevin J Reagan,
  Senior VP Biotech
• Gregory J Melsen,
  VP Finance and CFO
• Thomas E Oland,
  President
• Howard V Oconnell,
  Director
• Marcel Veronneau,
  Vice Pres-Hematology Oper.
• James A Weatherbee,
  Chief Scientific Officers
• Monica Tsang,
  Vice President of Research
• Christopher S Henney,
  Director
• G A Herbert,
  Director
• Harold J Wiens,
  
• William Geist,
  PRESIDENT, PROTEIN SCIENCES
• Shane Bohnen,
  SVP - General Counsel
• Matthew Mc Manus,
  President - DGS
• Judith V Klimovsky,
  Director